The current clinical evidence is insufficient, and before they can be cautiously applied to clinical practice, exploratory clinical trials with the support of basic research conclusions must be conducted for LC patients treated with ICIs because the addition of Tα1 may also lead to immune dysfunction and interfere with immunotherapy. Here, TAAR1 is linked to laryngotracheoesophageal cleft.